Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials
Nelson Wang, Katie Harris, John Chalmers, Stephen Harrap, Giuseppe Mancia, Michel Marre, Neil Poulter, Christophe Tzourio, Bryan Williams, Sophia Zoungas, Mark Woodward, Anthony Rodgers
JOURNAL OF HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021
OBJECTIVES: To assess the effects of combination BP lowering on cardiovascular events and mortality in the presence of aspirin and/or statin therapy in a combined analysis of the ADVANCE and PROGRESS trials. METHODS: We conducted an analysis of 14 682 participants allocated combination therapy with perindopril and indapamide or placebo followed up for a mean of 4.2 years. Participants were stratified into four groups defined by background use of medications at baseline: statin, aspirin, both or neither. Linear mixed effect models were used to assess differences in BP and Cox proportional hazard models were used to estimate the risks of major cardiovascular events, all-cause mortality and tre..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
the ADVANCE trial (ClinicalTrials.gov registration no. NCT00145925) was funded by grants from the National Health and Medical Research Council (NHMRC) of Australia (project grant ID 211086 and program grant IDs 358395 and 571281) and from Servier.